<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579653</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201903471</org_study_id>
    <nct_id>NCT04579653</nct_id>
  </id_info>
  <brief_title>Pupillometry and Locus Coeruleus Activation (PuLCA)</brief_title>
  <acronym>PuLCA</acronym>
  <official_title>Effects of Various Non-invasion Stimulation Parameters on Pupil Dilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will apply non-invasive, trans-cutaneous vagal nerve stimulation using various&#xD;
      stimulation parameters to young, healthy adults to find the optimal set of parameters to&#xD;
      elicit pupil response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study has a within-subjects design with a randomization of the order of tVNS administered parameters</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular response after transcutaneous nerve stimulation</measure>
    <time_frame>Visit 1 day</time_frame>
    <description>Number of participants with pupil response after transcutaneous nerve stimulation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Visual Impairment</condition>
  <condition>Ocular Illness</condition>
  <arm_group>
    <arm_group_label>Group A: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within-subjects design with a randomization of the order of tVNS administered parameters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Within-subjects design with a randomization of the order of tVNS administered parameters</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous electrical nerve stimulation devices</intervention_name>
    <description>electrical stimulation through surface electrodes</description>
    <arm_group_label>Group A: Experimental</arm_group_label>
    <arm_group_label>Group B: Active Comparator</arm_group_label>
    <other_name>Digitimer DS7A, Ultima Neo, or InTENSity EX4.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fluent English speaker with reading and writing proficiency.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with significant visual impairment or ocular illness may be excluded at&#xD;
             the discretion of the principal investigator.&#xD;
&#xD;
          -  Major medical illnesses including severe neurological illness (e.g. stroke, seizure&#xD;
             history), autoimmune disorders, and severe psychiatric diseases (e.g., schizophrenia)&#xD;
&#xD;
          -  Any history of brain surgery, tumor, intracranial metal implantation, pacemakers, or&#xD;
             other implanted devices.&#xD;
&#xD;
          -  Current (i.e. within 48 hours of the session) prescription medication or&#xD;
             over-the-counter medication use.&#xD;
&#xD;
          -  Illicit alcohol or drug use. Caffeine (e.g, coffee, energy drinks) consumption prior&#xD;
             to the visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Porges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Porges, PhD</last_name>
    <phone>3522945838</phone>
    <email>eporges@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

